<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6DB08663-5F52-4E8C-9D92-3D4FF7D769AB"><gtr:id>6DB08663-5F52-4E8C-9D92-3D4FF7D769AB</gtr:id><gtr:name>Heptares Therapeutics Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6DB08663-5F52-4E8C-9D92-3D4FF7D769AB"><gtr:id>6DB08663-5F52-4E8C-9D92-3D4FF7D769AB</gtr:id><gtr:name>Heptares Therapeutics Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D55E165-233B-426B-B629-5FFC887C1004"><gtr:id>5D55E165-233B-426B-B629-5FFC887C1004</gtr:id><gtr:name>MRC Technology (MRCT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/72A73B18-2D53-451A-9ED2-EB5BB7E83050"><gtr:id>72A73B18-2D53-451A-9ED2-EB5BB7E83050</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>G</gtr:otherNames><gtr:surname>Tate</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C3BF9C4F-1D15-4FA6-B19A-5CFE3DF475A2"><gtr:id>C3BF9C4F-1D15-4FA6-B19A-5CFE3DF475A2</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Greig</gtr:otherNames><gtr:surname>Leslie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U105197215"><gtr:id>24081D79-9355-4F1D-9737-253DC04D77DA</gtr:id><gtr:title>Structure of medically-important membrane proteins</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U105197215</gtr:grantReference><gtr:abstractText>We aim to understand the three-dimensional structure of proteins in the membrane of cells. This will lead to knowledge of how they work, which will help in designing drugs to treat a variety of different diseases such as cancer, obesity, heart problems and asthma.
Discovering the structure of proteins found within membranes is very challenging. They are present in very small amounts and are very unstable. We have developed a number of techniques to produce them in the laboratory and to make them stable enough to determine their structures.
We use cutting-edge methodology for determining the structures. We can grow crystals of the proteins and then use powerful X-ray sources to produce data from which the structures can be determined. More recently, we have used electron microscopy that is capable of visualising single molecules. By combining data from thousands of images, we can determine a structure.
Comparing structures with different drugs bound allows us to understand how the protein works. This helps pharmaceutical companies develop new drugs that are more powerful and have fewer side effects than existing drugs.</gtr:abstractText><gtr:technicalSummary>Integral membrane proteins are fundamental to the survival of all cells. Transporters allow essential nutrients to be taken up by the cell and other transporters excrete toxic metabolites. Receptors in the plasma membrane bind signalling molecules and transduce signals into the cytoplasm, thus giving multicellular organisms exquisite control over cellular functions. Although great progress has been made in understanding some of these transport and signalling processes, more membrane protein structures are required in different conformational states to allow a molecular understanding of transport and signalling. This is particularly the case for mammalian membrane proteins, which are usually unstable in detergents and often difficult to purify in a functional state. We have developed a methodology to stabilise membrane proteins by systematic mutagenesis that locks them preferentially in a single conformation, which makes them ideal for crystallography. We have now determined multiple structures of the ?1-adrenoceptor (?1AR), the adenosine A2A receptor (A2AR) and our collaborator has determined the structure of the neurotensin receptor. From these structures we have learnt how agonists activate the receptors and what defines whether a ligand is an agonist, a partial agonist or an inverse agonist. These structures also have a direct impact on drug design, because the ligands we have co-crystallised with ?1AR are used for the treatment of cardiovascular disease (beta blockers) and for treating asthma. Agonists to the A2AR are also used in the clinic to treat heart failure, whilst antagonists are being developed to treat cancer. I was a co-founder of the company Heptares Therapeutics, which is using structure based drug design for the development of new drugs targeting GPCRs involved in neurological disorders and metabolic disease, with a number of compounds now entering clinical trials.

The structures we have determined to date give a lot of detail on how ligands activate the receptor, but we also need structures of the receptors bound to G proteins and arrestin to explain fully the pharmacological activity of different ligands. We have therefore stabilised a portion of a heterotrimeric G protein to develop a novel entity, a mini G protein, that behaves pharmacologically the same way as a heterotrimeric G protein, but is easy to express and purify, it is highly stable and can be crystallised as a complex with GPCRs. We have recently determined the high resolution structure of the adenosine A2A receptor in the fully active state bound to mini-Gs, which has elucidated the relative roles of the agonist and the G protein in producing the active state of the adenosine receptor. Mini G proteins will enhance our ability to determine the structure of any GPCR in the fully active, something that was previously extremely difficult to perform.

Our work is externally supported by grants from the European Research Council and Heptares. Heptares Therapeutics Ltd, was created with support from MRCT and MVM in July 2007, and uses conformational thermostabilisation of GPCRs as a foundation for their work in drug design on important therapeutic drug targets. Our work is likely, in the long term, to continue to be useful for rational drug design, and we will therefore continue to translate our research findings into new therapeutic treatments of clinical relevance.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-05-18</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>6448341</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Technology (MRCT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Thermostabilisation of GPCRs</gtr:description><gtr:id>0202BF4C-7D53-423B-A6A4-726477F84A26</gtr:id><gtr:impact>7 papers
Several patents were filed
A spin-out company was formed (Heptares Therapeutics)</gtr:impact><gtr:outcomeId>SX4bywkqFY9-2</gtr:outcomeId><gtr:partnerContribution>MRCT were extremely helpful in formulating the IP generated with this project and the formation of the start-up company Heptares Therapeutics</gtr:partnerContribution><gtr:piContribution>We did all the work n this project, including GPC, expression, thermostabilisation, purification, crystallisation and structure determination.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heptares Therapeutics Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Heptares Therapeutics</gtr:description><gtr:id>8321B25E-78E1-4AE8-B7D0-4771607044B4</gtr:id><gtr:impact>8 papers have been published with co-authors from both the LMB and Heptares
5 papers were published by postdocs funded by Heptares (without co-authors from Heptares)
8 patents have been submitted
Multidisciplinary: membrane protein biochemistry, pharmacology, structural biology</gtr:impact><gtr:outcomeId>PXkAfghy5Si-1</gtr:outcomeId><gtr:partnerContribution>They have contributed intellectually to discussions on GPCR structures.Heptares have also performed pharmacological characterisation of some of the key mutants we have made. 
Heptares has provided funding for postdocs in our group, at a rate of one postdoc per year for the last 9 years.</gtr:partnerContribution><gtr:piContribution>We generated a thermostable mutant of the adenosine A2a receptor, characterised it pharmacologically, purified and crystallised it and determined 2 structures, one with adenosine bound and one with NECA bound.
We have engineered a minimal G protein to allow the structure determination of GPCRs in their fully activated state.
We have determined the structure of the adenosine A2a receptor in the fully active state bound to mini-Gs and an agonist
We have developed a panel of mini-G proteins to bind to any GPCR</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Biology &amp; Biophysics, Sandwich</gtr:department><gtr:description>Thermostabilisation of GPCRs</gtr:description><gtr:id>74DABFCB-3186-434E-A5BB-39DF803F9C06</gtr:id><gtr:impact>7 papers
Several patents were filed
A spin-out company was formed (Heptares Therapeutics)</gtr:impact><gtr:outcomeId>SX4bywkqFY9-1</gtr:outcomeId><gtr:partnerContribution>MRCT were extremely helpful in formulating the IP generated with this project and the formation of the start-up company Heptares Therapeutics</gtr:partnerContribution><gtr:piContribution>We did all the work n this project, including GPC, expression, thermostabilisation, purification, crystallisation and structure determination.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Life of a research technician</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5BD09AB3-384B-4C53-8BB6-F497ED48ED52</gtr:id><gtr:impact>Interview of my lab technician to find out the role of the job and what it was like to work in the LMB for over 30 years. Disseminate this information to interested parties via a weblink.</gtr:impact><gtr:outcomeId>56c5b84553ef04.64420498</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://thelongandshort.org/spaces/practical-science-interview-lab-technician</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Festival Cambridge</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>850362D7-67D6-4CA6-980B-84F119D5F80A</gtr:id><gtr:impact>Introduced children to cell biology by showing them how to prepare biological samples (their own cheek buccal cells) and how cells of multicellular organisms look under the microscope.</gtr:impact><gtr:outcomeId>56c5b769caa504.81612092</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Material World, live on Radio 4</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F0F4BC30-660D-41B5-BA6A-58F51B357A34</gtr:id><gtr:impact>Difficult to assess, although many people listened to the discussion

Useful publicity and I hope it led to some understanding about membrane proteins</gtr:impact><gtr:outcomeId>HAiuP7V3guN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Queen's visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>449FDE14-E63C-4E14-8669-45C3897DF579</gtr:id><gtr:impact>Her Majesty the Queen did not seem overtly impressed by our break-though in the structure determination of GPCRs or the founding of the drug company Heptares Therapeutics

None</gtr:impact><gtr:outcomeId>5452535ac65d27.03968616</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>142256</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Drug Initiativeon Channels and Transporters HEALTH-201924</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>HEALTH-201924</gtr:fundingRef><gtr:id>5AF424EE-7619-438A-A6F5-15E925FBA6B8</gtr:id><gtr:outcomeId>Yn4xEzcxjLo0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>603571</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pfizer Grant</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>0809E815-B6C7-4221-AFE0-5F846F6213DA</gtr:id><gtr:outcomeId>56c30ba632f005.54265454</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>351990</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Improving membrane protein expression 1R01GM095685-01</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:fundingRef>1R01GM095685-01</gtr:fundingRef><gtr:id>303C9FC8-B108-4033-B77C-6D379D09274A</gtr:id><gtr:outcomeId>RX6VC22iT6C0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>296293</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Heptares funded postdoc</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>Heptares Therapeutics Ltd</gtr:fundingOrg><gtr:id>B4F76561-9EAF-46C2-B284-C01E32771DF3</gtr:id><gtr:outcomeId>589b50efbdbeb8.25127023</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2378161</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Seventh Framework &amp;quot;Ideas&amp;quot; specific programme, Advanced Grant EMPSI 339995</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef>339995 EMPSI</gtr:fundingRef><gtr:id>AE2F8CE5-6681-45F2-9423-047C76BF7CC7</gtr:id><gtr:outcomeId>g8JssYaZzx8</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>391707</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stabilisation of unstable eukaryotic membrane proteins WT087731MA</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>WT087731MA</gtr:fundingRef><gtr:id>9DD9241E-82EE-4EF3-B1ED-11CA444747D9</gtr:id><gtr:outcomeId>RxDYEpTwknt0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>149304</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Folding of the beta adrenoceptor BB/G003653/1</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/G003653/1</gtr:fundingRef><gtr:id>63F28909-09DA-4985-8818-83A455BA7EF3</gtr:id><gtr:outcomeId>c2nSRaK5Xxy0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>370000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Thermostabilisation of GPCRs: Development Gap Fund</gtr:description><gtr:end>2008-02-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>F4FF18F0-652A-4841-AD62-7DC6CF045417</gtr:id><gtr:outcomeId>P9CfrYMJ9xG0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>183095</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Heptares</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>Heptares Therapeutics Ltd</gtr:fundingOrg><gtr:id>F2DCCD49-E419-4FC9-9826-089DDCEA52D2</gtr:id><gtr:outcomeId>544925fb85b8f3.58333497</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Improved methdlogy for finding thermostabilising mutations in GPCRs</gtr:description><gtr:grantRef>MC_U105197215</gtr:grantRef><gtr:id>460D2999-1E38-493D-B342-B291880C2F5B</gtr:id><gtr:impact>Consolidation of Heptares therapeutics</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>589ca0d78392e8.26267727</gtr:outcomeId><gtr:patentId>WO2010149964</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>MUTANT STABILISED G- PROTEIN COUPLED RECEPTORS, THEIR USES AND METHODS PRODUCING THEM</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Improved methods for the detection of thermostabilising mutations in GPCRs</gtr:description><gtr:grantRef>MC_U105197215</gtr:grantRef><gtr:id>E2008AC6-848D-44D6-9365-C0CE5CE52F46</gtr:id><gtr:impact>Founding or Heptares Therapeutics</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>589c9e77525374.76730194</gtr:outcomeId><gtr:patentId>WO2009071914</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Mutant proteins and methods for producing them</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Structure of the beta 1 adrenergic receptor bound to cyanopindolol</gtr:description><gtr:grantRef>MC_U105197215</gtr:grantRef><gtr:id>DF7B46CE-A05F-4D95-9043-45215A9E24E2</gtr:id><gtr:impact>Helped in the foundation of Heptares Therapeutics</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>589ca028d80f50.84934628</gtr:outcomeId><gtr:patentId>WO2008068534</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Crystal structure of ?-adrenergic receptor</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Thermostabilisation of the adenosine A2a receptor in an agonist bound state</gtr:description><gtr:grantRef>MC_U105197215</gtr:grantRef><gtr:id>F05845C1-D3D0-4965-8694-2AF3B955C500</gtr:id><gtr:impact>Excellent paper in Nature</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>589ca198781b36.25335700</gtr:outcomeId><gtr:patentId>WO2012120315</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>MUTANT PROTEINS AND METHODS FOR PRODUCING THEM</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Thermostabilisation of the serotonin transporter</gtr:description><gtr:grantRef>MC_U105197215</gtr:grantRef><gtr:id>1DD0DD1D-B9F7-4D30-A3DD-E3D655392282</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>589ca28e4eb179.39486400</gtr:outcomeId><gtr:patentId>WO2014140586</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>MUTANT MEMBRANE PROTEINS AND METHODS FOR THEIR PRODUCTION</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular conformation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed.</gtr:description><gtr:grantRef>MC_U105197215</gtr:grantRef><gtr:id>FE63FB8C-D78F-4A34-A05E-FB152770C91C</gtr:id><gtr:impact>These have all been exclusively assigned to a new MRC start-up called Heptares Therapeutics Limited. &amp;not;&amp;pound;26 million have been raised from venture capital companies so far, from MVM, Clarus and Novartis Venture Fund. 120 people are now employed in further developing the technology.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>Xd4xqohHcXF</gtr:outcomeId><gtr:patentId>WO2008114020</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Mutant proteins and methods for selecting them</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Improved method for finding thermostabilising mutations in GPCRs.</gtr:description><gtr:grantRef>MC_U105197215</gtr:grantRef><gtr:id>63203BB4-6F41-49EC-85AA-F2CBE39DFEB3</gtr:id><gtr:impact>Founding of Heptares Therapeutics</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>589c9fab68f6f6.62784566</gtr:outcomeId><gtr:patentId>WO2009101383</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Mutant proteins and methods for selecting them</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Structure determination of the adenosine A2a receptor bound to agonists</gtr:description><gtr:grantRef>MC_U105197215</gtr:grantRef><gtr:id>EA8A08B9-6CC1-42F2-9743-793D72302BD6</gtr:id><gtr:impact>Paper in Nature</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>589ca216c59835.57752680</gtr:outcomeId><gtr:patentId>WO2012137012</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>CRYSTAL STRUCTURE OF AN A2A ADENOSINE RECEPTOR</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Heptares Therapeutics Ltd</gtr:companyName><gtr:description>Heptares is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs). The company is currently leveraging its GPCR expertise and proprietary StaR&amp;reg; technology to build a pipeline of best-in-class and first-in-class GPCR-targeted medicines for the treatment of CNS, metabolic and other diseases. Heptares has raised over &amp;pound;26 million in venture capital funding. In 2016 Heptares was acquired for $400 million by Sosei Holdings. It has continued in its current format, but has expanded its operations, including the acquisition of G7, which is now re-named as Heptares Zurich.</gtr:description><gtr:id>BB37FEA3-AE1E-46DF-B12B-8D10109BA47F</gtr:id><gtr:impact>Recent deals includes a $3.3 billion agreement between Heptares and Allergan to take a series of muscarnic M1 agonists through the clinical after phase 1b trials were concluded successfully. Another deal is with AZ to take the adenosine A2a receptor inverse agonist into combination trials for the treatment of solid tumours.</gtr:impact><gtr:outcomeId>i4kmQzLQTp8</gtr:outcomeId><gtr:url>http://www.heptares.com/</gtr:url><gtr:yearCompanyFormed>2007</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>8313F0BB-3375-4224-ACFC-8E1958611113</gtr:id><gtr:title>Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43425f1acf151f249bff6c720fcdec2f"><gtr:id>43425f1acf151f249bff6c720fcdec2f</gtr:id><gtr:otherNames>Lebon G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>56c3074498c820.94434466</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72B480A4-1C03-4CD3-9122-4214A6A754E3</gtr:id><gtr:title>Biophysical fragment screening of the ?1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4b12b32ed65eea701e03ef917a41098"><gtr:id>a4b12b32ed65eea701e03ef917a41098</gtr:id><gtr:otherNames>Christopher JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>doi_55f94b94b78f0efa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D2E3CD8-966D-4A7A-A0C1-1B91733128EF</gtr:id><gtr:title>Strategy for the Thermostabilization of an Agonist-Bound GPCR Coupled to a G Protein.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e44a7f075337bc8f2676201c01ba00de"><gtr:id>e44a7f075337bc8f2676201c01ba00de</gtr:id><gtr:otherNames>Strege A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0076-6879</gtr:issn><gtr:outcomeId>5a802c737383c1.79808556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4576DF21-2DE8-4F2E-B8B1-FFC56C99E769</gtr:id><gtr:title>Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound ?1-Adrenergic Receptor.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b34f051a6d324501f8092747b6455b7"><gtr:id>0b34f051a6d324501f8092747b6455b7</gtr:id><gtr:otherNames>Sato T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>56c30744c8ee88.82923087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3B09807-3AAB-4425-98A6-662953A7BB41</gtr:id><gtr:title>High-throughput screening and selection of mammalian cells for enhanced protein production.</gtr:title><gtr:parentPublicationTitle>Biotechnology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fcfdade092503f3ecd558343da17f3c0"><gtr:id>fcfdade092503f3ecd558343da17f3c0</gtr:id><gtr:otherNames>Priola JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1860-6768</gtr:issn><gtr:outcomeId>589b4bd9479c62.00700894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>131C3E6A-AFA0-4F6A-9937-990D03975EC9</gtr:id><gtr:title>Thermostabilisation of an agonist-bound conformation of the human adenosine A(2A) receptor.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43425f1acf151f249bff6c720fcdec2f"><gtr:id>43425f1acf151f249bff6c720fcdec2f</gtr:id><gtr:otherNames>Lebon G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>oeSB5cp1pto</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C806CFE-D3DA-4543-ACB3-D123BB3B0F32</gtr:id><gtr:title>Expression and Purification of Mini G Proteins from.</gtr:title><gtr:parentPublicationTitle>Bio-protocol</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60efe25d068dc25ecbedc467ee5fd357"><gtr:id>60efe25d068dc25ecbedc467ee5fd357</gtr:id><gtr:otherNames>Carpenter B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2331-8325</gtr:issn><gtr:outcomeId>5a31e017b4a900.68582661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BFFDAB9-D6EA-452F-9D73-AF4E54A13662</gtr:id><gtr:title>Engineering a minimal G protein to facilitate crystallisation of G protein-coupled receptors in their active conformation.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60efe25d068dc25ecbedc467ee5fd357"><gtr:id>60efe25d068dc25ecbedc467ee5fd357</gtr:id><gtr:otherNames>Carpenter B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn><gtr:outcomeId>589b4bd96d2664.14332490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DF64696-62F7-480E-9373-B6C55971BA6C</gtr:id><gtr:title>Quality control in eukaryotic membrane protein overproduction.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c067156da69befb2aa778324cee050f"><gtr:id>8c067156da69befb2aa778324cee050f</gtr:id><gtr:otherNames>Thomas J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>56c3074547ced6.08582571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3611AC57-5438-4F1F-8396-C53EC36050D5</gtr:id><gtr:title>Expression, Purification and Crystallisation of the Adenosine AReceptor Bound to an Engineered Mini G Protein.</gtr:title><gtr:parentPublicationTitle>Bio-protocol</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60efe25d068dc25ecbedc467ee5fd357"><gtr:id>60efe25d068dc25ecbedc467ee5fd357</gtr:id><gtr:otherNames>Carpenter B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2331-8325</gtr:issn><gtr:outcomeId>5a31e0006a6e70.43114565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3406DEA5-12B8-4BE6-BFF7-528CD1333C6C</gtr:id><gtr:title>Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24350937170b5f61ed107861205615d1"><gtr:id>24350937170b5f61ed107861205615d1</gtr:id><gtr:otherNames>Venkatakrishnan AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>585d6b89041b57.22762348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72E2956B-B050-4914-90AC-9EC78D840868</gtr:id><gtr:title>Insight into partial agonism by observing multiple equilibria for ligand-bound and G-mimetic nanobody-bound ?-adrenergic receptor.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ec95141facd8ccfd28fe2ef1d91fe91"><gtr:id>0ec95141facd8ccfd28fe2ef1d91fe91</gtr:id><gtr:otherNames>Solt AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a802c739ac117.61459952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9ACDA9C8-496E-4DA6-B89B-EF68B07E230D</gtr:id><gtr:title>Rare coding variants of the adenosine A3 receptor are increased in autism: on the trail of the serotonin transporter regulome.</gtr:title><gtr:parentPublicationTitle>Molecular autism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fade30134abc26751f4ec948d7b844d0"><gtr:id>fade30134abc26751f4ec948d7b844d0</gtr:id><gtr:otherNames>Campbell NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_12623_23_23953133</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>053489B3-70D0-4481-942D-1AD90D4A6DAF</gtr:id><gtr:title>Ligand occupancy in crystal structure of ?1-adrenergic G protein-coupled receptor.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cb77a3f175ce4e5b99c271a376429e7"><gtr:id>9cb77a3f175ce4e5b99c271a376429e7</gtr:id><gtr:otherNames>Leslie AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>56c5af33aa7074.04284112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79615C40-D927-4116-BD59-83D60DF61431</gtr:id><gtr:title>Pharmacology and structure of isolated conformations of the adenosine A2A receptor define ligand efficacy.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9be8a4fea3a901a85b7fcf450fd0484"><gtr:id>f9be8a4fea3a901a85b7fcf450fd0484</gtr:id><gtr:otherNames>Bennett KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>doi_12623_112_084509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F689FD02-462A-4A2B-9EF8-3A3CF2E2F11C</gtr:id><gtr:title>The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (?36) deletions essential for crystallisation of the turkey ?-adrenoceptor.</gtr:title><gtr:parentPublicationTitle>Naunyn-Schmiedeberg's archives of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef5c711eb03a444e3f040bba5f06159c"><gtr:id>ef5c711eb03a444e3f040bba5f06159c</gtr:id><gtr:otherNames>Baker JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-1298</gtr:issn><gtr:outcomeId>dkcesvD1qqi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C57FB53C-03B1-448F-AFDD-DF32CB176ECA</gtr:id><gtr:title>[Structure of the adenosine-bound conformation of the human adenosine A(2A) receptor].</gtr:title><gtr:parentPublicationTitle>Medecine sciences : M/S</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43425f1acf151f249bff6c720fcdec2f"><gtr:id>43425f1acf151f249bff6c720fcdec2f</gtr:id><gtr:otherNames>Lebon G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0767-0974</gtr:issn><gtr:outcomeId>pm_12623_23_22130015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04464DE4-32F9-4BBB-BDAC-F3A5F2AE01ED</gtr:id><gtr:title>The 2.1 &amp;Aring; resolution structure of cyanopindolol-bound ?1-adrenoceptor identifies an intramembrane Na+ ion that stabilises the ligand-free receptor.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42fc964e9a17cb4aa4a27503281402ed"><gtr:id>42fc964e9a17cb4aa4a27503281402ed</gtr:id><gtr:otherNames>Miller-Gallacher JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54490fed04ff72.88844420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95257067-98E5-4AEC-A026-3D431F521733</gtr:id><gtr:title>Active state structures of G protein-coupled receptors highlight the similarities and differences in the G protein and arrestin coupling interfaces.</gtr:title><gtr:parentPublicationTitle>Current opinion in structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60efe25d068dc25ecbedc467ee5fd357"><gtr:id>60efe25d068dc25ecbedc467ee5fd357</gtr:id><gtr:otherNames>Carpenter B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-440X</gtr:issn><gtr:outcomeId>5a360ea1637531.28788291</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>350276A1-CBDB-4EF8-B5DB-36A89666AA79</gtr:id><gtr:title>Engineering an ultra-thermostable ?(1)-adrenoceptor.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14ffa188b8772eefcffb5bf60b6e81aa"><gtr:id>14ffa188b8772eefcffb5bf60b6e81aa</gtr:id><gtr:otherNames>Miller JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>ARDSM6L12SD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02855C2D-8A77-443B-BAE4-AABD0CA3E9A0</gtr:id><gtr:title>Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4dc73707bfdfa556b802d42be2974508"><gtr:id>4dc73707bfdfa556b802d42be2974508</gtr:id><gtr:otherNames>Dor? AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>d2u5Py81zPR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1A50BD0-A990-4ACD-909C-FED1D7A8E635</gtr:id><gtr:title>Molecular signatures of G-protein-coupled receptors.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24350937170b5f61ed107861205615d1"><gtr:id>24350937170b5f61ed107861205615d1</gtr:id><gtr:otherNames>Venkatakrishnan AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>doi_12623_ature11896</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E8E39A4-DCB2-4B01-AE10-2B52CE061D3B</gtr:id><gtr:title>Rapid Computational Prediction of Thermostabilizing Mutations for G Protein-Coupled Receptors.</gtr:title><gtr:parentPublicationTitle>Journal of chemical theory and computation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b8abe38e22f15b1844b333f10ad538b"><gtr:id>2b8abe38e22f15b1844b333f10ad538b</gtr:id><gtr:otherNames>Bhattacharya S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-9618</gtr:issn><gtr:outcomeId>56c30745801f54.85261416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>607074B4-80A3-46CA-B045-78BB2A06CB03</gtr:id><gtr:title>GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014.</gtr:title><gtr:parentPublicationTitle>Naunyn-Schmiedeberg's archives of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e05e0105e572646df2303f64b894c5"><gtr:id>e0e05e0105e572646df2303f64b894c5</gtr:id><gtr:otherNames>Heifetz A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-1298</gtr:issn><gtr:outcomeId>56c30743ed95f8.65879487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2FE108F-E91B-44A8-A6D3-4A064AC815B9</gtr:id><gtr:title>Purification and Crystallization of a Thermostabilized Agonist-Bound Conformation of the Human Adenosine A(2A) Receptor.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3d1bb467c9a9b6b1af4649dc5d94ea9"><gtr:id>a3d1bb467c9a9b6b1af4649dc5d94ea9</gtr:id><gtr:otherNames>Tate CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56c30745068a07.57921072</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17B53654-0A1F-4E98-A573-2C5E056BA38D</gtr:id><gtr:title>Structure of the agonist-bound neurotensin receptor.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba73f00365034e63eabb5e3ebbd30fd8"><gtr:id>ba73f00365034e63eabb5e3ebbd30fd8</gtr:id><gtr:otherNames>White JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>doi_12623_ature11558</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B63ABFA7-DF88-4F9F-8B17-653208504B4D</gtr:id><gtr:title>Stabilized G protein binding site in the structure of constitutively active metarhodopsin-II.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30d849de11c6cbdf47fa87c4629e96c5"><gtr:id>30d849de11c6cbdf47fa87c4629e96c5</gtr:id><gtr:otherNames>Deupi X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_12623_23_22198838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A8D0452-47BF-4530-9C59-A0E2904DB23D</gtr:id><gtr:title>Two distinct conformations of helix 6 observed in antagonist-bound structures of a beta1-adrenergic receptor.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f325ee2468867aaaec862512de7aa85c"><gtr:id>f325ee2468867aaaec862512de7aa85c</gtr:id><gtr:otherNames>Moukhametzianov R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>C198E5UXSG6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D93E61C6-7377-4D5B-9969-978AAA0435D7</gtr:id><gtr:title>Structural biology: A receptor that might block itself.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3d1bb467c9a9b6b1af4649dc5d94ea9"><gtr:id>a3d1bb467c9a9b6b1af4649dc5d94ea9</gtr:id><gtr:otherNames>Tate CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5a802dba0a2990.79066960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B865E4B4-B90A-427D-BEA6-E161CDAECE60</gtr:id><gtr:title>A crystal clear solution for determining G-protein-coupled receptor structures.</gtr:title><gtr:parentPublicationTitle>Trends in biochemical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3d1bb467c9a9b6b1af4649dc5d94ea9"><gtr:id>a3d1bb467c9a9b6b1af4649dc5d94ea9</gtr:id><gtr:otherNames>Tate CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0968-0004</gtr:issn><gtr:outcomeId>doi_55f94b94b782baf5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC13C1C8-0194-462F-95CD-A2F48714D916</gtr:id><gtr:title>Structural dynamics and thermostabilization of neurotensin receptor 1.</gtr:title><gtr:parentPublicationTitle>The journal of physical chemistry. B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3acac7c5b4963e152e4fb1d9049083f"><gtr:id>e3acac7c5b4963e152e4fb1d9049083f</gtr:id><gtr:otherNames>Lee S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1520-5207</gtr:issn><gtr:outcomeId>5675e14f9e277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88E05B16-35CC-4F89-9B97-8DE92E1CF445</gtr:id><gtr:title>Thermostabilization of the ?1-adrenergic receptor correlates with increased entropy of the inactive state.</gtr:title><gtr:parentPublicationTitle>The journal of physical chemistry. B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95621df04a906ffe4ba6a41e39211cd2"><gtr:id>95621df04a906ffe4ba6a41e39211cd2</gtr:id><gtr:otherNames>Niesen MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1520-5207</gtr:issn><gtr:outcomeId>doi_12623__jp403207c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C713DA8-3338-42C5-A61C-E5F2526E6B46</gtr:id><gtr:title>A mutagenesis and screening strategy to generate optimally thermostabilized membrane proteins for structural studies.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f64c0ee50590f1b8bdd63854bba594d"><gtr:id>0f64c0ee50590f1b8bdd63854bba594d</gtr:id><gtr:otherNames>Magnani F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn><gtr:outcomeId>589b4bd9ab3ce2.04778397</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DFC5A0C-49E8-4995-962B-DA3F9E46C187</gtr:id><gtr:title>Editorial overview: New constructs and expression of proteins: Making things better.</gtr:title><gtr:parentPublicationTitle>Current opinion in structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77ba703ea8980917235b50c1e4bcdcbc"><gtr:id>77ba703ea8980917235b50c1e4bcdcbc</gtr:id><gtr:otherNames>Takagi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-440X</gtr:issn><gtr:outcomeId>54490fecbd33c6.07425092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD8383B8-C110-433D-AD6D-528B620BA0F8</gtr:id><gtr:title>How Do Short Chain Nonionic Detergents Destabilize G-Protein-Coupled Receptors?</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3acac7c5b4963e152e4fb1d9049083f"><gtr:id>e3acac7c5b4963e152e4fb1d9049083f</gtr:id><gtr:otherNames>Lee S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>589b4bd98f5ec5.55125988</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CAA7D9D-790D-4683-B37F-5925BD655A26</gtr:id><gtr:title>The importance of interactions with helix 5 in determining the efficacy of ?-adrenoceptor ligands.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16e358d7ed8ed9d826b3972c81abba6b"><gtr:id>16e358d7ed8ed9d826b3972c81abba6b</gtr:id><gtr:otherNames>Warne T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>doi_12623_ST20120228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C5B72FB-E73E-408A-B5C2-6A643FA5F819</gtr:id><gtr:title>Generation of Tetracycline-Inducible Mammalian Cell Lines by Flow Cytometry for Improved Overproduction of Membrane Proteins.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53f5cfccc8b27d8ad19873c9864b6d99"><gtr:id>53f5cfccc8b27d8ad19873c9864b6d99</gtr:id><gtr:otherNames>Andr?ll J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>589b4bd9cc4427.24365566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>148FFF46-28F0-4228-A897-58D4DF1639CD</gtr:id><gtr:title>Overcoming barriers to membrane protein structure determination.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/affc477b16c011ace6a096118cb529cf"><gtr:id>affc477b16c011ace6a096118cb529cf</gtr:id><gtr:otherNames>Bill RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>pm_12623_23_21478852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2900BB69-9720-407C-B794-85537D357AC4</gtr:id><gtr:title>Outrunning free radicals in room-temperature macromolecular crystallography.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4f1c99931c6c1d5c36e707ced494be2"><gtr:id>f4f1c99931c6c1d5c36e707ced494be2</gtr:id><gtr:otherNames>Owen RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>pm_12623_23_22751666</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10C3DEAE-ED86-4BC2-B1A0-E1E63ACB2561</gtr:id><gtr:title>Complete Reversible Refolding of a G-Protein Coupled Receptor on a Solid Support.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/169a19052ba9fe7b9e6ca4b2b6d8945a"><gtr:id>169a19052ba9fe7b9e6ca4b2b6d8945a</gtr:id><gtr:otherNames>Di Bartolo N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>589b4bd9eefb62.02448893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C9CB61F-2569-4FDE-925B-053366960ECB</gtr:id><gtr:title>Structure of the adenosine A(2A) receptor bound to an engineered G protein.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60efe25d068dc25ecbedc467ee5fd357"><gtr:id>60efe25d068dc25ecbedc467ee5fd357</gtr:id><gtr:otherNames>Carpenter B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>585d6b7f050352.31222222</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBF4D4F9-472A-4D5C-851F-999D180B4133</gtr:id><gtr:title>The structural basis of agonist-induced activation in constitutively active rhodopsin.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42b8f3f4fca4094abb8345e7b487dc85"><gtr:id>42b8f3f4fca4094abb8345e7b487dc85</gtr:id><gtr:otherNames>Standfuss J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_12623_23_21389983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26181ABF-9993-49B1-B218-4425998ED181</gtr:id><gtr:title>Crystal structures of a stabilized ?1-adrenoceptor bound to the biased agonists bucindolol and carvedilol.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16e358d7ed8ed9d826b3972c81abba6b"><gtr:id>16e358d7ed8ed9d826b3972c81abba6b</gtr:id><gtr:otherNames>Warne T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>pm_12623_23_22579251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C25D33C-2A89-4C99-B730-316BB10907D4</gtr:id><gtr:title>The structural basis for agonist and partial agonist action on a ?(1)-adrenergic receptor.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16e358d7ed8ed9d826b3972c81abba6b"><gtr:id>16e358d7ed8ed9d826b3972c81abba6b</gtr:id><gtr:otherNames>Warne T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>A1F28DB4_9A1F28DB4_9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14D9E490-6BF2-43CD-9F1C-D9855ED175E5</gtr:id><gtr:title>Dynamic behavior of the active and inactive states of the adenosine A(2A) receptor.</gtr:title><gtr:parentPublicationTitle>The journal of physical chemistry. B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3acac7c5b4963e152e4fb1d9049083f"><gtr:id>e3acac7c5b4963e152e4fb1d9049083f</gtr:id><gtr:otherNames>Lee S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1520-5207</gtr:issn><gtr:outcomeId>544e790331f559.27098461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1673A491-61C4-402E-886A-838DBD0C5992</gtr:id><gtr:title>Three-dimensional structure of TspO by electron cryomicroscopy of helical crystals.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/524281bdef0ba75cf4cfe26e07670890"><gtr:id>524281bdef0ba75cf4cfe26e07670890</gtr:id><gtr:otherNames>Korkhov VM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>FdXdLyaz8Lz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D27A768-5188-4E17-8CFC-3A444AF21F89</gtr:id><gtr:title>Thermostabilisation of the serotonin transporter in a cocaine-bound conformation.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0e41fb6c0f6b2f2e21b8195c056e7fc"><gtr:id>f0e41fb6c0f6b2f2e21b8195c056e7fc</gtr:id><gtr:otherNames>Abdul-Hussein S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>doi_12623_013_03_025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C760784B-045F-4FE5-BB8B-88B636BB439F</gtr:id><gtr:title>Isolation and characterisation of transport-defective substrate-binding mutants of the tetracycline antiporter TetA(B).</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28bd948d23d5ea4c104c8d1477f6bc70"><gtr:id>28bd948d23d5ea4c104c8d1477f6bc70</gtr:id><gtr:otherNames>Wright DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>56c5af33d8f514.66316384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E077EC62-350D-4DA8-92D3-1F214F13B699</gtr:id><gtr:title>[G protein-coupled receptors in the spotlight].</gtr:title><gtr:parentPublicationTitle>Medecine sciences : M/S</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43425f1acf151f249bff6c720fcdec2f"><gtr:id>43425f1acf151f249bff6c720fcdec2f</gtr:id><gtr:otherNames>Lebon G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0767-0974</gtr:issn><gtr:outcomeId>pm_12623_23_23067420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>800B199A-E34C-4D8F-80DF-EE1C5606D6D4</gtr:id><gtr:title>Advances in membrane protein crystallography: in situ and in meso data collection.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0732d22890f2b0274b12426a3ac04f7"><gtr:id>e0732d22890f2b0274b12426a3ac04f7</gtr:id><gtr:otherNames>Weyand S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>56c305f6cd5fe5.48488806</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64CB7FD3-D95A-4671-ADA0-34A75B00C5AC</gtr:id><gtr:title>Mini-G proteins: Novel tools for studying GPCRs in their active conformation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4316c4762a7b17d1ec72026ac9300010"><gtr:id>4316c4762a7b17d1ec72026ac9300010</gtr:id><gtr:otherNames>Nehm? R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a2fd717c50f30.54712260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89144C64-EAB3-4709-BAEE-B1D90D64BDDF</gtr:id><gtr:title>A class of mild surfactants that keep integral membrane proteins water-soluble for functional studies and crystallization.</gtr:title><gtr:parentPublicationTitle>Molecular membrane biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf19a4b3b11b13ebd353f8307897b609"><gtr:id>bf19a4b3b11b13ebd353f8307897b609</gtr:id><gtr:otherNames>Hovers J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0968-7688</gtr:issn><gtr:outcomeId>F58wYqTad6V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDBAABC9-E59D-495D-B796-5ED5FB9DEC9C</gtr:id><gtr:title>Optimising the combination of thermostabilising mutations in the neurotensin receptor for structure determination.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/662cf1635068eec68ebb91c77269236c"><gtr:id>662cf1635068eec68ebb91c77269236c</gtr:id><gtr:otherNames>Shibata Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>doi_12623_013_01_008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A0F9750-96B1-4C0F-B800-534F3BE64CF6</gtr:id><gtr:title>Agonist-bound structures of G protein-coupled receptors.</gtr:title><gtr:parentPublicationTitle>Current opinion in structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43425f1acf151f249bff6c720fcdec2f"><gtr:id>43425f1acf151f249bff6c720fcdec2f</gtr:id><gtr:otherNames>Lebon G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-440X</gtr:issn><gtr:outcomeId>doi_55f94b94b778ecde</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C99E2CD-B07B-4D26-85A9-1BACBC39099A</gtr:id><gtr:title>Reversible swelling of SBMV is associated with reversible disordering.</gtr:title><gtr:parentPublicationTitle>Journal of structural biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad7968d586527c1fd3f76aeabf35ac38"><gtr:id>ad7968d586527c1fd3f76aeabf35ac38</gtr:id><gtr:otherNames>Li J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1047-8477</gtr:issn><gtr:outcomeId>5a802c73416862.93615518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED6C5E64-11F6-4681-BA47-E6A719F330A0</gtr:id><gtr:title>Universal allosteric mechanism for Ga activation by GPCRs.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68b3df48a4df99da1bae0cd9acb4c97e"><gtr:id>68b3df48a4df99da1bae0cd9acb4c97e</gtr:id><gtr:otherNames>Flock T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5675e7f27b3d5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1920FB81-CAEC-409E-9EF7-13B622E27E32</gtr:id><gtr:title>Practical aspects in expression and purification of membrane proteins for structural analysis.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df5a2fdb0720651e9d64218b2f35521a"><gtr:id>df5a2fdb0720651e9d64218b2f35521a</gtr:id><gtr:otherNames>Vinothkumar KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_12623_23_23132053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DE11223-209B-4C75-AAC4-5DF9D9AC4440</gtr:id><gtr:title>How Can Mutations Thermostabilize G-Protein-Coupled Receptors?</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5034a7ba438c445aa7cebfc0d27fda6"><gtr:id>c5034a7ba438c445aa7cebfc0d27fda6</gtr:id><gtr:otherNames>Vaidehi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>56c307443211d3.30369120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD08617F-5C02-4829-AA55-4A20C4C227E4</gtr:id><gtr:title>Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43425f1acf151f249bff6c720fcdec2f"><gtr:id>43425f1acf151f249bff6c720fcdec2f</gtr:id><gtr:otherNames>Lebon G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>fZ65hKtNspP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10EED71F-E1D9-486C-85EB-772F403924B7</gtr:id><gtr:title>Identifying Thermostabilizing Mutations in Membrane Proteins by Bioinformatics.</gtr:title><gtr:parentPublicationTitle>Biophysical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3d1bb467c9a9b6b1af4649dc5d94ea9"><gtr:id>a3d1bb467c9a9b6b1af4649dc5d94ea9</gtr:id><gtr:otherNames>Tate CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3495</gtr:issn><gtr:outcomeId>56c307446afa49.41256719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C786641D-1905-495A-B550-AC8FBFF71673</gtr:id><gtr:title>Overexpression of membrane proteins in mammalian cells for structural studies.</gtr:title><gtr:parentPublicationTitle>Molecular membrane biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53f5cfccc8b27d8ad19873c9864b6d99"><gtr:id>53f5cfccc8b27d8ad19873c9864b6d99</gtr:id><gtr:otherNames>Andr?ll J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0968-7688</gtr:issn><gtr:outcomeId>pm_12623_23_22963530</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U105197215</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>